Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16478
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSkrifvars, Markus B-
dc.contributor.authorBailey, Michael-
dc.contributor.authorPresneill, Jeffrey-
dc.contributor.authorFrench, Craig-
dc.contributor.authorNichol, Alistair-
dc.contributor.authorLittle, Lorraine-
dc.contributor.authorDuranteau, Jacques-
dc.contributor.authorHuet, Olivier-
dc.contributor.authorHaddad, Samir-
dc.contributor.authorArabi, Yaseen-
dc.contributor.authorMcArthur, Colin-
dc.contributor.authorCooper, D. James-
dc.contributor.authorBellomo, Rinaldo-
dc.date2016-12-27-
dc.date.accessioned2017-01-04T04:37:25Z-
dc.date.available2017-01-04T04:37:25Z-
dc.date.issued2017-03-
dc.identifier.citationIntensive Care Medicine 2017; 43(3): 419-428en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16478-
dc.description.abstractPURPOSE: To estimate the prevalence, risk factors, prophylactic treatment and impact on mortality for venous thromboembolism (VTE) in patients with moderate to severe traumatic brain injury (TBI) treated in the intensive care unit. METHODS: A post hoc analysis of the erythropoietin in traumatic brain injury (EPO-TBI) trial that included twice-weekly lower limb ultrasound screening. Venous thrombotic events were defined as ultrasound-proven proximal deep venous thrombosis (DVT) or clinically detected pulmonary embolism (PE). Results are reported as events, percentages or medians and interquartile range (IQR). Cox regression analysis was used to calculate adjusted hazard ratios (HR) with 95% confidence intervals (CI) for time to VTE and death. RESULTS: Of 603 patients, 119 (19.7%) developed VTE, mostly comprising DVT (102 patients, 16.9%) with a smaller number of PE events (24 patients, 4.0%). Median time to DVT diagnosis was 6 days (IQR 2-11) and to PE diagnosis 6.5 days (IQR 2-16.5). Mechanical prophylaxis (MP) was used in 91% of patients on day 1, 97% of patients on day 3 and 98% of patients on day 7. Pharmacological prophylaxis was given in 5% of patients on day 1, 30% of patients on day 3 and 57% of patients on day 7. Factors associated with time to VTE were age (HR per year 1.02, 95% CI 1.01-1.03), patient weight (HR per kg 1.01, 95% CI 1-1.02) and TBI severity according to the International Mission for Prognosis and Analysis of Clinical Trials risk of poor outcome (HR per 10% increase 1.12, 95% CI 1.01-1.25). The development of VTE was not associated with mortality (HR 0.92, 95% CI 0.51-1.65). CONCLUSIONS: Despite mechanical and pharmacological prophylaxis, VTE occurs in one out of every five patients with TBI treated in the ICU. Higher age, greater weight and greater severity of TBI increase the risk. The development of VTE was not associated with excess mortality.en_US
dc.subjectErythropoietinen_US
dc.subjectDeep venous thrombosisen_US
dc.subjectPulmonary embolismen_US
dc.subjectTraumatic brain injuryen_US
dc.subjectVenous thromboembolismen_US
dc.titleVenous thromboembolic events in critically ill traumatic brain injury patientsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleIntensive Care Medicineen_US
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDivision of Intensive Care, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University and Helsinki University Hospital, Helsinki, Finlanden_US
dc.identifier.affiliationDepartment of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Intensive Care, Western Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Medicine and Medical Sciences, University College Dublin, Dublin, Irelanden_US
dc.identifier.affiliationDepartment of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDépartement d'Anesthésie-Réanimation, Hôpital de Bicêtre, Assistance Publique des Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, Franceen_US
dc.identifier.affiliationDepartment of Anaesthesiology and Intensive care medicine, CHRU La Cavale Blanche, Université de Bretagne Occidentale, Brest, Franceen_US
dc.identifier.affiliationKing Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabiaen_US
dc.identifier.affiliationDepartment of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealanden_US
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28028552en_US
dc.identifier.doi10.1007/s00134-016-4655-2en_US
dc.contributor.corpauthorEPO-TBI investigators-
dc.contributor.corpauthorANZICS Clinical Trials Group-
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherBellomo, Rinaldo
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.